Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb;21(2):77-87.
doi: 10.1038/s41584-024-01189-3. Epub 2024 Dec 2.

HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity

Affiliations
Review

HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity

Fatemeh Navid et al. Nat Rev Rheumatol. 2025 Feb.

Abstract

HLA-B*27 confers a strong risk of developing spondyloarthritis (SpA), which includes axial SpA with or without peripheral arthritis, enthesitis, acute anterior uveitis and gastrointestinal inflammation. Although no definitive mechanism has been established to explain the role of this HLA class I protein in the pathogenesis of SpA, three main hypotheses have emerged. First is the idea that self-peptides displayed by HLA-B27 resemble microorganism-derived peptides, leading to the expansion of autoreactive CD8+ T cells that trigger disease. The second and third hypotheses focus on aberrant properties of HLA-B27, including its tendency to form cell-surface dimers that can activate innate killer immunoglobulin-like receptors on CD4+ T helper 17 cells, triggering the production of pathogenic cytokines. HLA-B27 also misfolds in the endoplasmic reticulum, which can activate the unfolded protein response, increasing IL-23 expression and thereby promoting the production of type 17 cytokines. HLA-B27 misfolding in mesenchymal stem cells has also been linked to enhanced bone formation by mesenchymal stem cell-derived osteoblasts, which could contribute to structural damage in axial SpA. In this Review we summarize prevailing ideas about the role of HLA-B27 in SpA, discuss the latest developments as well as the gaps in current knowledge, and provide recommendations for future research to address these unmet needs.

PubMed Disclaimer

Conflict of interest statement

Competing interests: R.A.C. has received funding from Novartis, L.C. has received funding from Novartis, P.B. has received institutional research funding from Merck, Benevolent AI, GSK, Regeneron and Novartis.

References

    1. Rudwaleit, M. et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68, 777–783 (2009). - PubMed
    1. Taurog, J. D., Chhabra, A. & Colbert, R. A. Ankylosing spondylitis and axial spondyloarthritis. N. Engl. J. Med. 375, 1303 (2016). - PubMed
    1. Brewerton, D. A. et al. Ankylosing spondylitis and HL-A 27. Lancet 1, 904–907 (1973). - PubMed
    1. Caffrey, M. F. & James, D. C. Human lymphocyte antigen association in ankylosing spondylitis. Nature 242, 121 (1973). - PubMed
    1. Schlosstein, L., Terasaki, P. I., Bluestone, R. & Pearson, C. M. High association of an HL-A antigen, W27, with ankylosing spondylitis. N. Engl. J. Med. 288, 704–706 (1973). - PubMed

LinkOut - more resources